Skip to main content

Advertisement

Table 1 Patients’ characteristics

From: Phase I clinical study of multiple epitope peptide vaccine combined with chemoradiation therapy in esophageal cancer patients

Patient no. Dose of peptides (mg) HLA Age (Y) Gender Stage* PS** Target organ
1 0.5 A2402 59 M IIA 0 Primary tumor
2 0.5 A2402 58 M IIB 0 Primary tumor
Lymph node
3 0.5 A2402 69 F IVA 1 Primary tumor
Lymph node
4 1.0 A2402 64 M III 2 Primary tumor
Lymph node
5 1.0 A2402 65 M III 2 Primary tumor
Lymph node
6 1.0 A2402 61 M III 0 Primary tumor
Lymph node
7 3.0 A2402 70 M IIB 0 Primary tumor
Lymph node
8 3.0 A2402 63 M IVA 0 Primary tumor
Lymph node
9 3.0 A2402 67 M IVB 0 Primary tumor
Lymph node
Adrenal gland
10 3.0 A2402 71 M III 0 Primary tumor
Lymph node
11 3.0 A2402 67 M IVB 0 Primary tumor
Lymph node
Lung
  1. *Stage according to the TNM classification for esophageal cancer (UICC).
  2. **PS: Performance status (ECOG).